ESMO: Where will Merck, Eisai take Keytruda-Lenvima next? Ovarian and colorectal cancer could be good options, data show

Merck & Co. already has an approval for Keytruda in tandem with Lenvima—a drug it shares with Eisai—in endometrial cancer. But the partners are trying to take the combo into additional cancers, and new data provide a glimpse of where it might go next.